CARLSBAD, Calif., June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® ...
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker ...
ZURICH, Sept 14 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approveddrug Evrysdi have previously ...
A five-year-old boy who received the world's most expensive drug as a baby has made "incredible progress" and can walk independently, his mother said. Edward, from Colchester, has spinal muscular ...
Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA) in some children. A healthcare professional will administer the drug as a one-time intravenous infusion. Doctors determine the ...
Harvard's Chris Gerry, Ph.D. has previously written about Zolgensma, the world's most expensive drug, and some of the economics behinds its price. Is Zolgensma, the only treatment for spinal muscular ...
CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) ...
Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback